Neuren Pharmaceuticals Limited (ASX:NEU)

Revenue by Segment

Financials in millions AUD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Commercial Products	64.63M	213.24M	231.93M	14.55M	-
Commercial Products Growth	-69.69%	-8.06%	1493.66%	-	-
Corporate	15.00K	3.59M	17.00K	-	-
Corporate Growth	-99.58%	21011.76%	-	-	-
Pharmaceutical Products	-	-	-	-	3.20M
Pharmaceutical Products Growth	-	-	-	-	345.89%
Total	64.65M	216.83M	231.94M	14.55M	3.20M
Total Growth	-70.18%	-6.51%	1493.77%	355.21%	345.89%

Revenue by Geography

Financials in millions AUD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
United States	64.63M	213.24M	-	-	-
United States Growth	-69.69%	-	-	-	-
Total	64.63M	213.24M	-	-	-
Total Growth	-69.69%	-	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 14, 2026

Data Sources Report a data error